Correct Answer: A. Decreased citrate excretion
Hydrochlorothiazide (HCTZ) is contraindicated in patients with a history of renal stones, yet it is often mistakenly prescribed for hypertension in such patients. The mechanism of stone formation with HCTZ involves metabolic derangements that promote lithogenesis. HCTZ causes hypercalciuria (increased urinary calcium excretion) and hypokalemia (potassium depletion). The hypokalemia leads to metabolic alkalosis, which in turn causes decreased urinary citrate excretion (citrate is reabsorbed in the proximal tubule when pH is alkaline). Citrate is a natural stone inhibitor—it chelates calcium and prevents crystal aggregation. When citrate excretion falls, the inhibitory effect is lost, promoting calcium oxalate and calcium phosphate stone formation. Additionally, HCTZ increases serum uric acid levels, promoting uric acid stones. The decreased citrate excretion is the PRIMARY pathophysiological mechanism explaining why HCTZ worsens nephrolithiasis. This is a critical DOC error in Indian clinical practice, where HCTZ remains a first-line antihypertensive despite this contraindication in stone-formers. Better alternatives include ACE inhibitors, ARBs, or calcium channel blockers, which do not promote stone formation.
Why the other options are wrong
B. Increased calcium excretion — This statement is actually TRUE regarding HCTZ mechanism, but it is NOT the answer to why HCTZ is contraindicated in renal stones. The question asks which statement is TRUE regarding the CHOICE of drug (i.e., why it should NOT be chosen). Increased calcium excretion is a consequence, not the primary reason for contraindication. The trap is that students confuse the mechanism (hypercalciuria) with the explanation for the contraindication. The real answer focuses on the secondary effect: decreased citrate excretion due to metabolic alkalosis. C. Increased oxalate absorption — HCTZ does not increase oxalate absorption from the GI tract. Oxalate metabolism is independent of thiazide action. This is a distractor that confuses GI absorption with renal handling. Some students may think HCTZ causes diarrhea (which it doesn't significantly), leading to increased oxalate reabsorption, but this is not a recognized mechanism. The question is specifically about renal stone pathophysiology, not GI absorption. D. Decreased calcium excretion — This is the OPPOSITE of what HCTZ does. HCTZ causes hypercalciuria (increased urinary calcium), not decreased calcium excretion. This is a classic NBE trap—students who know HCTZ affects calcium handling but misremember the direction may select this. Decreased calcium excretion would actually be protective against stone formation, making HCTZ a good choice—but it is not what happens clinically.
High-Yield Facts
- Hydrochlorothiazide causes hypercalciuria (increased urinary calcium), which is the primary driver of calcium stone formation.
- Metabolic alkalosis from HCTZ-induced hypokalemia reduces urinary citrate excretion, removing the natural stone inhibitor.
- Citrate is a chelating agent that binds calcium and prevents crystal aggregation; low citrate = high stone risk.
- HCTZ is contraindicated in patients with nephrolithiasis history; ACE inhibitors, ARBs, or calcium channel blockers are safer alternatives.
- HCTZ also increases serum uric acid, promoting uric acid stone formation in addition to calcium stones.
- Thiazide-induced hypokalemia is the mechanism linking HCTZ to metabolic alkalosis and decreased citrate excretion.
Mnemonics
HCTZ Stone Risk (CHAP) Calcium ↑ (hypercalciuria), Hypokalemia → alkalosis, Alkalosis → citrate ↓, Promotes stones. Use this when deciding antihypertensives in stone-formers. Citrate = Stone Inhibitor Low citrate = Low inhibition = High stone risk. Alkalosis ↓ citrate reabsorption → ↓ urinary citrate. Remember: alkaline urine = citrate stays in blood, not urine.
NBE Trap
NBE pairs "increased calcium excretion" (which is true) with the question asking why HCTZ is a bad choice, trapping students who know the mechanism but confuse it with the explanation for contraindication. The real answer requires understanding the secondary consequence: decreased citrate excretion due to metabolic alkalosis.
Clinical Pearl
In Indian clinical practice, HCTZ remains a first-line antihypertensive despite this contraindication. Always screen hypertensive patients for stone history before prescribing HCTZ; if positive, switch to ACE inhibitors, ARBs, or amlodipine. A patient presenting with both hypertension and recurrent stones on HCTZ is a classic case of iatrogenic worsening.
_Reference: KD Tripathi Pharmacology Ch. 12 (Diuretics); Harrison Ch. 297 (Nephrolithiasis)_